Sellas Life Sciences Announces Successful Phase 3 Clinical Trial for Acute Myeloid Leukemia
SLS SELLAS Life Sciences Group Inc
$7.47 -4.96%
View chart & analysis → - 1Sellas Life Sciences announced that its pivotal Phase 3 Regal trial met its primary endpoint.
- 2GPS recorded a 41% reduction in the risk of death compared to best available therapy (BAT).
- 3SLS shares rose 7.1% in premarket trading.
So what's the key point?
Sellas Life Sciences achieved positive results in a leukemia treatment trial. The study reduced the risk of death by 41%, which may lead to a rise in the stock price.
Source Stocktwits +2 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.